首页> 美国卫生研究院文献>other >A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma
【2h】

A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma

机译:食管小细胞癌与基底膜鳞状细胞癌临床病理因素比较分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Esophageal small cell carcinoma (E-SmCC) and basaloid squamous cell carcinomas (BSCCs) are both highly aggressive malignancies, but their detailed differences in clinical behaviors have remained virtually unknown. In addition, treatment strategies of the patients with E-SmCC have not been established. 29 cases of E-SmCC and 39 with BSCC were examined in this study to clarify the clinical features and outcome of the patients with E-SmCC and to compare the findings with those of BSCC. E-SmCCs presented a more advanced status than BSCC (TNM Stage: P = .002). Esophagectomy was performed in 15 small cell carcinoma patients and 14 were treated with non-surgical/systemic therapy. The clinical outcome of the small cell carcinoma cases was significantly worse than those with BSCC (P = .001), but results of a stage-stratified analysis revealed that the Stage I small cell carcinoma patients presented favorable prognosis (3-year survival rate 100%, n = 4). In contrast, among those with Stage II–IV, clinical outcome tended to be better in the systemic therapy group (3-year survival rate 49%, n = 13) than the surgically treated group (3-year survival rate 0%, n = 12). E-SmCC was a more aggressive neoplasm than BSCC. However, early detection could possibly improve the clinical outcome of patients with E-SmCC. Systemic therapy could also benefit the patients with advanced disease (Stage II–IV).
机译:食管小细胞癌(E-SmCC)和基底基底鳞状细胞癌(BSCC)都是高度侵袭性的恶性肿瘤,但是它们在临床行为上的详细差异实际上仍然未知。另外,尚未建立E-SmCC患者的治疗策略。本研究检查了29例E-SmCC患者和39例BSCC患者,以阐明E-SmCC患者的临床特征和结局,并将其与BSCC患者的结果进行比较。 E-SmCC的状态比BSCC的状态更高级(TNM阶段:P = 0.002)。在15例小细胞癌患者中进行了食管切除术,其中14例接受了非手术/全身治疗。小细胞癌病例的临床结局显着低于BSCC(P = .001),但分期分析结果显示,I期小细胞癌患者预后良好(3年生存率100 %,n = 4)。相反,在II–IV期患者中,全身治疗组(3年生存率49%,n,= 13)的临床结果往往好于手术治疗组(3年生存率0%,n = 12)。 E-SmCC是比BSCC更具有侵略性的肿瘤。但是,早期发现可能会改善E-SmCC患者的临床结局。全身治疗也可以使晚期疾病(II-IV期)患者受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号